Fastest Growing Stocks
GLPG is part of our fastest growing stocks screen, indicating it has high EPS and sales growth.
GALAPAGOS NV-SPON ADR (GLPG) Stock Price & Overview
NASDAQ:GLPG • US36315X1019
Current stock price
29.2 USD
+0.04 (+0.14%)
Last:
The current stock price of GLPG is 29.2 USD. Today GLPG is up by 0.14%. In the past month the price decreased by -12.3%. In the past year, price increased by 18.25%.
GLPG Key Statistics
52-Week Range24.3106 - 37.78
Current GLPG stock price positioned within its 52-week range.
1-Month Range27.975 - 33.12
Current GLPG stock price positioned within its 1-month range.
- Market Cap
- 1.924B
- P/E
- 5.09
- Fwd P/E
- N/A
- EPS (TTM)
- 5.74
- Dividend Yield
- N/A
GLPG Stock Performance
Today
+0.14%
1 Week
+0.93%
1 Month
-12.30%
3 Months
-13.01%
Longer-term
6 Months -15.50%
1 Year +18.25%
2 Years +2.50%
3 Years -25.23%
5 Years -62.50%
10 Years -35.64%
GLPG Stock Chart
GLPG Stock Screens
GLPG currently appears in the following ChartMill screener lists.
Revenue Growth Leaders
GLPG is part of our revenue growth leaders stock screen, indicating it has strong recent and multi-year revenue growth.
High EPS Growth Stocks
GLPG occurs in our High EPS Growth Stocks screen list, indicating it is profitable, healthy and showing strong recent EPS growth.
Small Cap Growth Stocks
GLPG is part of our Small Cap Growth Stocks list, indicating it is a fast growing small cap stock.
GLPG Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to GLPG. When comparing the yearly performance of all stocks, GLPG turns out to be only a medium performer in the overall market: it outperformed 41.7% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
GLPG Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to GLPG. GLPG has an average financial health and profitability rating.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
GLPG Earnings
On February 24, 2026 GLPG reported an EPS of 11.87 and a revenue of 900.82M. The company beat EPS expectations (329.89% surprise) and beat revenue expectations (977.98% surprise).
Next Earnings DateMay 6, 2026
Last Earnings DateFeb 24, 2026
PeriodQ4 / 2025
EPS Reported€11.87
Revenue Reported900.822M
EPS Surprise 329.89%
Revenue Surprise 977.98%
GLPG Forecast & Estimates
18 analysts have analysed GLPG and the average price target is 35.42 USD. This implies a price increase of 21.29% is expected in the next year compared to the current price of 29.2.
For the next year, analysts expect an EPS growth of -141.18% and a revenue growth 0.26% for GLPG
Analysts
Analysts52.22
Price Target35.42 (21.3%)
EPS Next Y-141.18%
Revenue Next Year0.26%
GLPG Groups
Sector & Classification
GLPG Financial Highlights
Over the last trailing twelve months GLPG reported a non-GAAP Earnings per Share(EPS) of 5.74. The EPS increased by 334.82% compared to the year before.
Income Statements
Revenue(TTM)1.11B
Net Income(TTM)320.88M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 28.85% | ||
| ROA | 9.42% | ||
| ROE | 9.92% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%3023.68%
Sales Q2Q%1093.22%
EPS 1Y (TTM)334.82%
Revenue 1Y (TTM)280.53%
GLPG Ownership
Ownership
Inst Owners25.28%
Shares65.90M
Float49.19M
Ins Owners0%
Short Float %2.23%
Short Ratio7.36
GLPG Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 368.645B | ||
| AMGN | AMGEN INC | 15.21 | 187.715B | ||
| GILD | GILEAD SCIENCES INC | 15.68 | 173.485B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.54 | 112.351B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.99 | 79.706B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.88 | 44.214B | ||
| INSM | INSMED INC | N/A | 31.674B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 30.229B | ||
| NTRA | NATERA INC | N/A | 29.365B | ||
| BIIB | BIOGEN INC | 10.94 | 26.496B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.79 | 25.315B | ||
| MRNA | MODERNA INC | N/A | 21.519B | ||
| INCY | INCYTE CORP | 12.27 | 19.324B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GLPG
Company Profile
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Company Info
IPO: 2005-05-06
GALAPAGOS NV-SPON ADR
Generaal De Wittelaan L11 A3
MALINES (MECHELEN) ANTWERPEN 2800 BE
CEO: Onnovan deStolpe
Employees: 558
Phone: 3215342900
GALAPAGOS NV-SPON ADR / GLPG FAQ
What does GLPG do?
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. The company is headquartered in Malines (Mechelen), Antwerpen. The company went IPO on 2005-05-06. The firm is engaged in the discovery and development of small molecule medicines with modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. The firm focuses on developing a portfolio of clinical-stage therapies for the enhancement of existing treatment paradigms. The company develops transformational medicines in areas of high unmet need by combining internal with external science with the goal to add years of life and improve of life of patients across the globe. The company discovers which proteins that are involved in causing diseases such as, rheumatoid, arthritis, inflammatory bowel disease and fibrosis. The firm acquired CellPoint and AboundBio in order to develop a cell therapy, which is a potential transformative treatment of different types of cancer.
Can you provide the latest stock price for GALAPAGOS NV-SPON ADR?
The current stock price of GLPG is 29.2 USD. The price increased by 0.14% in the last trading session.
Does GALAPAGOS NV-SPON ADR pay dividends?
GLPG does not pay a dividend.
How is the ChartMill rating for GALAPAGOS NV-SPON ADR?
GLPG has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What is the analyst forecast for GLPG stock?
18 analysts have analysed GLPG and the average price target is 35.42 USD. This implies a price increase of 21.29% is expected in the next year compared to the current price of 29.2.
What is GALAPAGOS NV-SPON ADR worth?
GALAPAGOS NV-SPON ADR (GLPG) has a market capitalization of 1.92B USD. This makes GLPG a Small Cap stock.
Who owns GALAPAGOS NV-SPON ADR?
You can find the ownership structure of GALAPAGOS NV-SPON ADR (GLPG) on the Ownership tab.